BR112019028269A2 - polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão - Google Patents

polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão Download PDF

Info

Publication number
BR112019028269A2
BR112019028269A2 BR112019028269-6A BR112019028269A BR112019028269A2 BR 112019028269 A2 BR112019028269 A2 BR 112019028269A2 BR 112019028269 A BR112019028269 A BR 112019028269A BR 112019028269 A2 BR112019028269 A2 BR 112019028269A2
Authority
BR
Brazil
Prior art keywords
seq
amino acid
polypeptide
fact
acid sequence
Prior art date
Application number
BR112019028269-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Bridget Puffer
Julian Chandler
Nimish Gera
Douglas L. Sheridan
Siddharth Jindal
Paul P. Tamburini
Original Assignee
Alexion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.
Publication of BR112019028269A2 publication Critical patent/BR112019028269A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112019028269-6A 2017-07-11 2018-07-11 polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão BR112019028269A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531215P 2017-07-11 2017-07-11
US62/531,215 2017-07-11
PCT/US2018/041661 WO2019014360A1 (en) 2017-07-11 2018-07-11 POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF

Publications (1)

Publication Number Publication Date
BR112019028269A2 true BR112019028269A2 (pt) 2020-07-14

Family

ID=63036501

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019028269-6A BR112019028269A2 (pt) 2017-07-11 2018-07-11 polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão

Country Status (12)

Country Link
US (3) US11498960B2 (https=)
EP (1) EP3625265A1 (https=)
JP (3) JP7684803B2 (https=)
KR (3) KR102806328B1 (https=)
CN (3) CN111201246B (https=)
AU (3) AU2018301412B2 (https=)
BR (1) BR112019028269A2 (https=)
CA (1) CA3067247A1 (https=)
CO (1) CO2020000369A2 (https=)
IL (3) IL307197B2 (https=)
MX (2) MX2024005945A (https=)
WO (1) WO2019014360A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102806328B1 (ko) 2017-07-11 2025-05-14 알렉시온 파마슈티칼스, 인코포레이티드 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
US20210388070A1 (en) * 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
EP3956344A1 (en) * 2019-04-16 2022-02-23 University of Washington Amantadine binding protein
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
BR112022010742A2 (pt) 2019-12-26 2022-08-16 Eisai R&D Man Co Ltd Composição farmacêutica contendo ácido ribonucleico de fita dupla que inibe a expressão de c5 complementar
JP7343618B2 (ja) 2020-01-17 2023-09-12 オリンパス株式会社 発光装置、および駆動装置
EP4135837A1 (en) 2020-04-16 2023-02-22 Assistance Publique, Hopitaux De Paris Methods for treating a complement mediated disorder caused by viruses
IL301713A (en) * 2020-10-05 2023-05-01 Alexion Pharma Inc Methods for treating dermatomyositis
CN120018862A (zh) * 2022-08-31 2025-05-16 阿雷克森制药公司 用于治疗镰状细胞病的融合多肽的剂量和施用
CN116731149B (zh) * 2023-06-07 2024-02-27 华中农业大学 草鱼补体活化分子碳末端肽C5a-CP及应用
CN119241699B (zh) * 2024-09-24 2025-11-28 广州康盛生物科技股份有限公司 一种抗人补体c5的单域抗体及其应用
CN121518561A (zh) * 2025-12-24 2026-02-13 北京林业大学 一种PagRAP2.3蛋白点突变及其在植物愈伤再生中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7083784B2 (en) * 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
EP1558645B1 (en) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
AU2012254935B2 (en) * 2004-02-12 2014-05-29 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
TW200607523A (en) * 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN100368022C (zh) 2005-09-20 2008-02-13 中国人民解放军第二军医大学 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法
US7807409B2 (en) * 2005-10-21 2010-10-05 Roche Palo Alto Llc Method for the recombinant expression of a polypeptide
SG10201804008UA (en) 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
DK2262831T3 (en) 2008-03-03 2015-04-27 Novelmed Therapeutics Inc ANTI-Properdin ANTIBODIES
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
CA2766565A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP2531523A1 (en) * 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
CA2811221C (en) 2010-03-10 2018-01-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN103003296A (zh) 2010-07-09 2013-03-27 阿菲博迪公司 多肽
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
KR20140064768A (ko) 2011-07-01 2014-05-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-프로퍼딘 항체 및 그의 용도
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
WO2013102123A2 (en) 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
EP3511339B1 (en) 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
CA2887050A1 (en) 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
BR112016003142A2 (pt) 2013-08-28 2017-10-17 Swedish Orphan Biovitrum Ab Publ ligação de polipeptídeos estáveis ao c5 do complemento humano
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
MX2019008827A (es) 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
KR102806328B1 (ko) 2017-07-11 2025-05-14 알렉시온 파마슈티칼스, 인코포레이티드 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질

Also Published As

Publication number Publication date
JP7684803B2 (ja) 2025-05-28
RU2020102910A3 (https=) 2021-12-02
KR20200026264A (ko) 2020-03-10
MX2024005945A (es) 2024-06-11
US20250163138A1 (en) 2025-05-22
RU2020102910A (ru) 2021-08-11
CN111201246A (zh) 2020-05-26
AU2018301412A1 (en) 2020-01-30
IL324119A (en) 2025-12-01
US20230235033A1 (en) 2023-07-27
MX2024005946A (es) 2024-06-11
US11498960B2 (en) 2022-11-15
JP2023120208A (ja) 2023-08-29
IL271920A (en) 2020-02-27
JP2020532285A (ja) 2020-11-12
CN117327188A (zh) 2024-01-02
KR20250068795A (ko) 2025-05-16
CO2020000369A2 (es) 2020-01-31
JP2025118590A (ja) 2025-08-13
AU2018301412B2 (en) 2025-08-07
IL271920B2 (en) 2024-03-01
WO2019014360A1 (en) 2019-01-17
US12221473B2 (en) 2025-02-11
WO2019014360A8 (en) 2019-02-21
IL307197A (en) 2023-11-01
IL307197B2 (en) 2026-03-01
AU2018301412A9 (en) 2025-08-07
IL271920B1 (en) 2023-11-01
CA3067247A1 (en) 2019-01-17
EP3625265A1 (en) 2020-03-25
KR20250099285A (ko) 2025-07-01
AU2025200303A1 (en) 2025-02-13
IL307197B1 (en) 2025-11-01
CN117327187A (zh) 2024-01-02
US20200399351A1 (en) 2020-12-24
KR102806328B1 (ko) 2025-05-14
AU2025200313A1 (en) 2025-02-13
CN111201246B (zh) 2023-10-27

Similar Documents

Publication Publication Date Title
US12221473B2 (en) Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
ES2546943T3 (es) Polipéptidos, dominios variables de anticuerpo y antagonistas
JP2026053563A (ja) 補体関連疾患のための融合タンパク質構築物
TW201348256A (zh) Ｃｘ３ｃｒ１－結合多肽
JP2023535384A (ja) 抗ｐｄ－１抗体医薬組成物及びその用途
CN116284377A (zh) 抗人血管生成素3纳米抗体及其应用
TW202409074A (zh) 鬆弛素或類似物的融合蛋白及其醫藥用途
EP3992205A1 (en) Sars coronavirus-2 spike protein binding compounds
US10875918B2 (en) P2X7 receptor binders and polypeptides comprising the same
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
BR122025022103A2 (pt) Proteína de fusão, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira isolada, polipeptídeo manipulado, e método de preparação da proteína de fusão
HK40106012A (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
HK40106013A (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
HK40027205B (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
HK40027205A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
WO2025228370A1 (zh) 中和呼吸道合胞病毒的抗原结合蛋白及其应用
BR122021000901B1 (pt) Polipeptídeo, seu método de fabricação, célula hospedeira bacteriana, de levedura ou fúngica, composição farmacêutica, kit de diagnóstico, e método de diagnóstico
BR122021000924B1 (pt) Polipeptídeo, seu método de fabricação, célula hospedeira bacteriana, de levedura ou fúngica, composição farmacêutica, kit de diagnóstico, e método de diagnóstico
BR112014021080B1 (pt) Polipeptídeo, seu método de fabricação, célula hospedeira bacteriana, de levedura ou fúngica, composição farmacêutica, kit de diagnóstico, e método de diagnóstico

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025022103-1 PROTOCOLO 870250093162 EM 10/10/2025 19:11.